TL-895 and KRT-232 Study in Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory (R/R) FLT3+ Acute Myeloid LeukemiaMedDRA version: 21.1Level: LLTClassification code 10081514Term: Acute myeloid leukemia refractorySystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2020-003109-73-DE
- Lead Sponsor
- Telios Pharma, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 70
Subjects in the Phase 1b and Phase 2 Dose Expansion must meet all the following criteria in order to be eligible for the study:
1.Adults =18 years of age who are able to provide informed consent.
2.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
3.Documented primary TP53wt AML or TP53wt AML secondary to myelodysplastic syndrome (MDS), as defined by World Health Organization (WHO) criteria (Arber 2016).
4.Subject is refractory to and/or relapsed after at least one prior therapy with no alternative therapeutic options likely to produce clinical benefit. Subjects must have received a FLT3 inhibitor (unless contraindicated), if FLT3 inhibitors are approved and available in the country in which the subject is to be treated.
5.Presence of the FLT3 activating mutation TKD or FLT3-ITD in bone marrow or peripheral blood detected by a test approved by the local health authority or, if not available, by a validated test.
6.Adequate renal function within 7 days (Phase 1b) or 28 days (Phase 2) prior to the first dose of study treatment defined as an estimated creatinine clearance =30 mL/min by Cockcroft-Gault formula.
7.Adequate hepatic function within 7 days (Phase 1b) or 28 days (Phase 2) prior to the first dose of study treatment defined as:
a.Total serum bilirubin = 2.0 x ULN. Subjects with known Gilbert’s syndrome or disease-related hemolysis must have a total bilirubin =3.0 X ULN
b.Serum AST and/or ALT =2.5×ULN.
8.Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential must both use a highly effective contraception method during the study. In addition, after the last dose of study drug, female subjects must continue to use a highly effective method of contraception for 1 month and 1 week and male subjects must continue to use a highly effective method of contraception for 3 months and 1 week. A woman is considered of childbearing potential (ie, fertile, following menarche and until becoming post menopausal) unless permanently sterile.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 35
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 35
Subjects in the Phase 1b and Phase 2 Dose Expansion who meet any of the following criteria will not be eligible for the study:
1.Acute promyelocytic leukemia (AML subtype M3).
2.Subjects with known active central nervous system involvement with AML.
3.Prior treatment with MDM2 antagonist therapies.
4.Prior treatment with a BTK inhibitor.
5.Chemotherapy, cytoreductive therapy, immune therapy, cytokine therapy or any investigational therapy within 14 days prior to first dose of study treatment. Subjects on FLT3 inhibitor therapy must discontinue treatment at least 2 days prior to first dose of study drug.
6.Active participation in other therapeutic clinical trials including supportive care trials.
7.Allogeneic stem cell transplant within 3 months; autologous stem cell transplant within 3 months or active graft-versus-host disease prior to first dose of study treatment.
8.Subjects who are eligible for an allogeneic hematopoietic stem cell transplantation (HSCT) per the opinion of the investigator and have a donor. Subjects who are HSCT eligible in the opinion of the investigator, but who refuse a transplant, are eligible for the study.
9.Subjects with a history of bleeding diathesis; major hemorrhage or intracranial hemorrhage within 24 weeks prior to the first dose of study treatment
10.Known infection with human immunodeficiency virus.
11.Known active hepatitis B or C infection.
12.History of another malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non-metastatic prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection or superficial transitional cell bladder carcinoma.
13.Uncontrolled intercurrent illness including but not limited to clinically significant cardiac disease (New York Heart Class III or IV); symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or subjects with psychiatric illness/social situations that would limit compliance with study requirements; or subjects who have been committed to an institution by judicial or administrative authority.
14.Grade 2 or higher QTc prolongation >480 msec per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
15.History of myocardial infarction within 3 months of first dose of study treatment
16.History of major organ transplant
17.Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of the first dose of study drug.
18.Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole); subjects receiving PPIs who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study provided the proton pump inhibitor is discontinued at least 3 days prior to first dose of study drug.
19.Phase 1b only: Subjects receiving medications, herbal supplements, or food known to be strong inhibitors of CYP3A within 7 days prior to the first dose of TL-895
20.Having history of difficulty swallowing, gastric or small bowel surgery with history of malabsorption, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the KRT-232 or TL-895 treatment.
21.Major surgery or planned major surgery within 28 days prior to first dose of stu
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method